Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

/in
  • Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM 
London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration to access Syenex’s VivoCell Platform for the precise in vivo delivery of Leucid’s CAR-T assets including LEU011 for the treatment of solid tumours.
Read more…